Compare BG & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BG | RVMD |
|---|---|---|
| Founded | 1818 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 15.2B |
| IPO Year | N/A | 2020 |
| Metric | BG | RVMD |
|---|---|---|
| Price | $89.33 | $80.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $114.00 | $77.47 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 9.16 | N/A |
| EPS | ★ 8.69 | N/A |
| Revenue | ★ $60,109,000,000.00 | N/A |
| Revenue This Year | $28.45 | N/A |
| Revenue Next Year | $26.02 | $714.50 |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | ★ 10.29 | N/A |
| 52 Week Low | $67.40 | $29.17 |
| 52 Week High | $99.55 | $81.49 |
| Indicator | BG | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 70.27 |
| Support Level | $90.11 | $74.20 |
| Resistance Level | $93.93 | $80.44 |
| Average True Range (ATR) | 2.27 | 2.77 |
| MACD | -0.44 | -0.72 |
| Stochastic Oscillator | 7.38 | 88.05 |
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.